Polygenic Score Analyses on Antidepressant Response in Late-life Depression, Results from the IRL-GRey Study

Overview

Journal Pharmacogenomics J

Specialties Genetics
Molecular Biology
Pharmacology

Date 2024 Nov 23

PMID 39578436

Authors

Samar S M Elsheikh

Victoria S Marshe

Xiaoyu Men

Farhana Islam

Vanessa F Goncalves

Guillaume Pare

Daniel Felsky

James L Kennedy

Benoit H Mulsant

Charles F Reynolds 3rd

Eric J Lenze

Daniel J Muller

Affiliations

Soon will be listed here.

Abstract

Late-life depression (LLD) is often accompanied by medical comorbidities such as psychiatric disorders and cardiovascular diseases, posing challenges to antidepressant treatment. Recent studies highlighted significant associations between treatment-resistant depression (TRD) and polygenic risk score (PRS) for attention deficit hyperactivity disorder (ADHD) in adults as well as a negative association between antidepressant symptom improvement with both schizophrenia and bipolar. Here, we sought to validate these findings with symptom remission in LLD. We analyzed the Incomplete Response in Late Life Depression: Getting to Remission (IRL-GRey) sample consisting of adults aged 60+ with major depression (N = 342) treated with venlafaxine for 12 weeks. We constructed PRSs for ADHD, depression, schizophrenia, bipolar disorder, neuroticism, general intelligence, antidepressant symptom remission and antidepressant percentage symptom improvement using summary statistics from the Psychiatric Genomics Consortium and the GWAS Catalog. Logistic regression was used to test the association of PRSs with venlafaxine symptom remission and percentage symptom improvement, co-varying for the genomic principal components, age, sex and depressive symptoms severity at baseline. We found a nominal (i.e., p value ≤ 0.05) association between symptom remission and both PRS for ADHD and (OR = 1.36 [1.07, 1.73], p = 0.011) and PRS for bipolar disorder (OR = 0.75 [0.58, 0.97], p = 0.031), as well as between percentage symptom improvement and PRS for general intelligence (beta = 6.81 (SE = 3.122), p = 0.03). However, the ADHD association was in the opposite direction as expected, and both associations did not survive multiple testing corrections. Altogether, these findings suggest that previous findings regarding ADHD PRS and antidepressant response (measured with various outcomes) do not replicate in older adults.

References

Paolucci S . Epidemiology and treatment of post-stroke depression. Neuropsychiatr Dis Treat. 2008; 4(1):145-54. PMC: 2515899. DOI: 10.2147/ndt.s2017. View

Alexopoulos G, Meyers B, Young R, Campbell S, Silbersweig D, Charlson M . 'Vascular depression' hypothesis. Arch Gen Psychiatry. 1997; 54(10):915-22. DOI: 10.1001/archpsyc.1997.01830220033006. View

Davydow D, Levine D, Zivin K, Katon W, Langa K . The association of depression, cognitive impairment without dementia, and dementia with risk of ischemic stroke: a cohort study. Psychosom Med. 2015; 77(2):200-8. PMC: 4333011. DOI: 10.1097/PSY.0000000000000136. View

Tiwari A, Zai C, Altar C, Tanner J, Davies P, Traxler P . Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. Transl Psychiatry. 2022; 12(1):101. PMC: 8921325. DOI: 10.1038/s41398-022-01847-8. View

Marshe V, Islam F, Maciukiewicz M, Bousman C, Eyre H, Lavretsky H . Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. Am J Geriatr Psychiatry. 2020; 28(6):609-629. DOI: 10.1016/j.jagp.2020.01.007. View

Meerman J, Ter Hark S, Janzing J, Coenen M . The Potential of Polygenic Risk Scores to Predict Antidepressant Treatment Response in Major Depression: A Systematic Review. J Affect Disord. 2022; 304:1-11. DOI: 10.1016/j.jad.2022.02.015. View

Amare A, Schubert K, Tekola-Ayele F, Hsu Y, Sangkuhl K, Jenkins G . Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. Front Psychiatry. 2018; 9:65. PMC: 5845551. DOI: 10.3389/fpsyt.2018.00065. View

Amare A, Schubert K, Tekola-Ayele F, Hsu Y, Sangkuhl K, Jenkins G . The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. J Neural Transm (Vienna). 2019; 126(1):35-45. DOI: 10.1007/s00702-018-01966-x. View

Marshe V, Maciukiewicz M, Hauschild A, Islam F, Qin L, Tiwari A . Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Transl Psychiatry. 2021; 11(1):127. PMC: 7884410. DOI: 10.1038/s41398-021-01248-3. View

10.

Pain O, Hodgson K, Trubetskoy V, Ripke S, Marshe V, Adams M . Identifying the Common Genetic Basis of Antidepressant Response. Biol Psychiatry Glob Open Sci. 2022; 2(2):115-126. PMC: 9117153. DOI: 10.1016/j.bpsgos.2021.07.008. View

11.

Fabbri C, Hagenaars S, John C, Williams A, Shrine N, Moles L . Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. Mol Psychiatry. 2021; 26(7):3363-3373. PMC: 8505242. DOI: 10.1038/s41380-021-01062-9. View

12.

Tansey K, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A . Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2012; 73(7):679-82. DOI: 10.1016/j.biopsych.2012.10.030. View

13.

John C, Reeve N, Free R, Williams A, Ntalla I, Farmaki A . Cohort profile: Extended Cohort for E-health, Environment and DNA (EXCEED). Int J Epidemiol. 2019; 48(5):1734. PMC: 6857747. DOI: 10.1093/ije/dyz175. View

14.

Lenze E, Mulsant B, Blumberger D, Karp J, Newcomer J, Anderson S . Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386(10011):2404-12. PMC: 4690746. DOI: 10.1016/S0140-6736(15)00308-6. View

15.

Demontis D, Walters R, Martin J, Mattheisen M, Als T, Agerbo E . Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2018; 51(1):63-75. PMC: 6481311. DOI: 10.1038/s41588-018-0269-7. View

16.

Wray N, Ripke S, Mattheisen M, Trzaskowski M, Byrne E, Abdellaoui A . Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018; 50(5):668-681. PMC: 5934326. DOI: 10.1038/s41588-018-0090-3. View

17.

Trubetskoy V, Pardinas A, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli T . Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022; 604(7906):502-508. PMC: 9392466. DOI: 10.1038/s41586-022-04434-5. View

18.

van den Berg S, de Moor M, McGue M, Pettersson E, Terracciano A, Verweij K . Harmonization of Neuroticism and Extraversion phenotypes across inventories and cohorts in the Genetics of Personality Consortium: an application of Item Response Theory. Behav Genet. 2014; 44(4):295-313. PMC: 4057636. DOI: 10.1007/s10519-014-9654-x. View

19.

Savage J, Jansen P, Stringer S, Watanabe K, Bryois J, de Leeuw C . Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nat Genet. 2018; 50(7):912-919. PMC: 6411041. DOI: 10.1038/s41588-018-0152-6. View

20.

Montgomery S, Asberg M . A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382-9. DOI: 10.1192/bjp.134.4.382. View